Background
Phase III RCT (n=529, randomized 2:1), treatment-naive fit CLL patients ≤70 years. Patients with del(17p) were excluded. Compared ibrutinib+rituximab against the chemoimmunotherapy standard FCR.
Interventions and follow up
Arm A (IR): Ibrutinib 420 mg PO daily until progression/toxicity + rituximab (cycles 2-7)
Arm B (FCR): Fludarabine 25 mg/m2 + cyclophosphamide 250 mg/m2 days 1-3 + rituximab, x6 cycles Q28D
Primary endpoint: PFS
Median follow-up: 33.6 mo (primary); 5.8 yr (update)
Arm B (FCR): Fludarabine 25 mg/m2 + cyclophosphamide 250 mg/m2 days 1-3 + rituximab, x6 cycles Q28D
Primary endpoint: PFS
Median follow-up: 33.6 mo (primary); 5.8 yr (update)
Results
3-yr PFS: 89.4% vs 72.9% (A vs B); HR 0.35, 95%CI 0.22-0.56, P<.001
3-yr PFS, unmutated IGHV: 90.7% vs 62.5%
3-yr PFS, mutated IGHV: 87.7% vs 88%
3-yr OS: 98.8% vs 91.5%, HR 0.17, 95%CI 0.05-0.54, P<.001
5-yr PFS (all): 78% vs 51%, HR 0.37, 95%CI 0.27-0.51, P<.0001
5-yr PFS, unmutated IGHV: 75% vs 33%, HR 0.27, 95%CI 0.18-0.41, P<.0001
5-yr PFS, mutated IGHV: 83% vs 68%, HR 0.27, 95%CI 0.11-0.62, P=.001
3-yr PFS, unmutated IGHV: 90.7% vs 62.5%
3-yr PFS, mutated IGHV: 87.7% vs 88%
3-yr OS: 98.8% vs 91.5%, HR 0.17, 95%CI 0.05-0.54, P<.001
5-yr PFS (all): 78% vs 51%, HR 0.37, 95%CI 0.27-0.51, P<.0001
5-yr PFS, unmutated IGHV: 75% vs 33%, HR 0.27, 95%CI 0.18-0.41, P<.0001
5-yr PFS, mutated IGHV: 83% vs 68%, HR 0.27, 95%CI 0.11-0.62, P=.001
Adverse events
Hematologic/cytopenias (grade ≥3): Neutropenia 25.6% (IR) vs 44% (FCR).
Infections (grade ≥3): 10.5% vs 32% (FCR higher).
Cardiovascular: Atrial fibrillation 7.4% vs 3.2%; hypertension 18.8% vs 8.2%; cardiac toxicity 6.5% vs <1%.
Secondary malignancy (update): MDS/AML 0% vs 1.7%; second primary cancer 15.3% vs 9.1%. Deaths 4 vs 10 cases.
Infections (grade ≥3): 10.5% vs 32% (FCR higher).
Cardiovascular: Atrial fibrillation 7.4% vs 3.2%; hypertension 18.8% vs 8.2%; cardiac toxicity 6.5% vs <1%.
Secondary malignancy (update): MDS/AML 0% vs 1.7%; second primary cancer 15.3% vs 9.1%. Deaths 4 vs 10 cases.
Conclusions
Ibrutinib+rituximab improved PFS and OS over FCR in younger, fit treatment-naive CLL, with greatest benefit in unmutated IGHV. Mutated-IGHV patients had PFS similar to FCR. IR caused less neutropenia/infection but more atrial fibrillation and hypertension.
Key Limitations
Excluded del(17p) and patients >70y. Continuous indefinite ibrutinib raises cost, adherence, and cumulative cardiovascular toxicity concerns. Rituximab contribution to ibrutinib uncertain (later trials show no added benefit). No comparison to fixed-duration venetoclax-based regimens.
Clinical Context
Practice-changing: established BTK-inhibitor therapy as preferred frontline over FCR in younger fit CLL, per ESMO guidance, and contributed to FDA/EMA frontline ibrutinib approval. Chemoimmunotherapy now reserved largely for IGHV-mutated patients without other options; venetoclax-based fixed-duration regimens are alternatives.